Regarding the treatment against COVID-19, antiviral, anti-inflammatory, or anticoagulant drugs were administered to severe or critical patients, regardless of the presence of anti-IFN auto-abs (Table 2). This evidence concerns the gene IFNA1 and COVID-19.